#USA #Biopharmaceutical #Germantown #Precigen #PAPZIMEOS

Precigen's Transformative Year: Financial Results and Business Updates for 2025

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical leader focusing on innovative precision medicine, released its financial achievements and strategic developments for the whole year of 2025. This period has marked a significant transition for the company, particularly with the FDA approval of PAPZIMEOS, the first treatment of its kind for adults suffering from recurrent respiratory papillomatosis (RRP).

Milestones Achieved

In August 2025, the FDA granted approval for PAPZIMEOS (zopapogene imadenovec-drba), validating Precigen's therapeutic approach in addressing RRP. Following this pivotal endorsement, the company recorded net product revenue of $3.4 million in the fourth quarter of 2025, reflecting its initial commercial sales in the U.S. This approval has set the stage for a growing demand, evidenced by continued positive patient response into the first quarter of 2026.

The Centers for Medicare and Medicaid Services bolstered the accessibility of PAPZIMEOS by assigning a permanent J-code (J3404), effective April 1, 2026. This coding is essential as it simplifies the claims process, ensuring broader patient access to the treatment.

Recommendations and Clinical Studies

Notably, an expert consensus paper sponsored by the Recurrent Respiratory Papillomatosis Foundation, authored by a panel of 16 leading RRP specialists, has recognized PAPZIMEOS as the new first-line treatment standard for adults in the U.S. This endorsement underscores the therapy's significant safety and efficacy profile, along with its compelling response durability observed to date.

Moreover, Precigen has initiated an open-label redosing study to further evaluate the treatment's retreatment efficacy in RRP patients, a critical step towards optimizing patient care and management.

Financial Overview

As of December 31, 2025, Precigen reported cash, cash equivalents, and investments totaling $100.4 million, which are projected to sustain the company through cash flow break-even by the end of 2026. The company's financial results reflect substantial growth, with total revenues increasing by $5.8 million compared to the previous year, driven primarily by PAPZIMEOS sales and enhanced collaboration revenue.

Expenses have also fluctuated. While research and development costs decreased due to the closure of ActoBio operations, selling, general, and administrative expenses surged by nearly 70%, reflecting the company's heavy investment into the commercialization of PAPZIMEOS.

This period also saw an increase in net loss attributable to common shareholders, totaling $429.6 million, primarily because of non-cash liabilities adjustments and preferred stock adjustments during stock conversions. However, the context for this loss is vital, as it corresponds with the significant advancements being realized within the company's operational framework and product lines.

Looking Ahead

Speaking on the future prospects, Dr. Helen Sabzevari, President and CEO of Precigen, emphasized the momentum gained within the medical community regarding PAPZIMEOS as the first-line treatment for adults with RRP. She expressed enthusiasm for sharing further progress updates during subsequent calls, particularly concerning early sales momentum in 2026.

The commercial launch of PAPZIMEOS signifies a pivotal moment not only for Precigen but for the broader field, enhancing treatment options for individuals battling RRP and demonstrating the company’s commitment to innovation within precision medicine.

In summary, 2025 has proven to be a transformative year for Precigen, characterized by strategic advancements, financial growth, and increased patient access to critical therapies. With upcoming developments on the horizon, it will be intriguing to follow how Precigen continues to navigate this evolving landscape.